Provectus Biopharmaceuticals Inc.

351 articles about Provectus Biopharmaceuticals Inc.

• Provectus Biopharmaceuticals Inc. Completes Patient Accrual For PH-10 Phase II Clinical Study Of Cellular And Immunologic Changes In The Skin

  9/21/2015

• Provectus Biopharmaceuticals Inc. Awarded U.S. Patent Protecting Use Of PV-10 As Part Of Combination Therapy For Cancer

  8/18/2015

• Provectus Biopharmaceuticals Inc. Reports Second Quarter 2015 Financial Results

  8/6/2015

• Provectus Biopharmaceuticals Inc. Will Hold Its 2015 Second Quarter Business Update Conference Call On Thursday, August 6, 2015, At 4 PM Eastern Daylight Time

  7/22/2015

• Provectus Biopharmaceuticals Inc., Sinopharm-China State Institute Of Pharmaceutical Industry And Sinopharm A-Think Pharmaceutical Co., Ltd Continue Search For Agreement On PV-10 Use In China

  7/16/2015

• Provectus Biopharmaceuticals Inc.’ Data On PV-10 For Chemoablation Of Liver Cancers Presented At ESMO 17th World Congress On Gastrointestinal Cancer

  7/2/2015

• Provectus Biopharmaceuticals Inc. Signs Letter Of Intent With Boehringer Ingelheim (China) To Collaborate In Bringing PV-10 To Market In China

  7/2/2015

• Provectus Biopharmaceuticals Inc.’ Data On PV-10 As Treatment For Melanoma Presented At 5th European Post-Chicago Melanoma / Skin Cancer Meeting

  6/26/2015

• AAPI Honors Provectus Biopharmaceuticals Inc. During 33rd Annual Convention And Scientific Assembly

  6/26/2015

• Provectus Biopharmaceuticals Inc.’ Poster Presentation Displayed On Phase 3 Study Of PV-10 At 5th European Post-Chicago Melanoma / Skin Cancer Meeting

  6/25/2015

• Provectus Biopharmaceuticals Inc. Announces Closing Of Public Offering

  6/25/2015

• Provectus Biopharmaceuticals Inc. Announces Abstract Available On PV-10 For Chemoablation Of Liver Cancers At ESMO 17th World Congress On Gastrointestinal Cancer

  6/25/2015

• Provectus Biopharmaceuticals Inc. Retains PharmaHEALTHLabs To Facilitate Investigator Advisory Board Meeting During 11Th Brazilian Melanoma Conference

  6/22/2015

• Provectus Biopharmaceuticals Inc. Announces Proposed Public Offering Of Common Stock And Warrants

  6/19/2015

• Provectus Biopharmaceuticals Inc. Announces Pricing Of Public Offering To Raise $13.1 Million

  6/19/2015

• Abstract On Provectus Biopharmaceuticals Inc.’ PV-10 In Colon Cancer Models Published By Society Of Surgical Oncology

  6/16/2015

• BIO2015: Provectus Biopharmaceuticals Inc. To Present At 2015 BIO International Convention In Philadelphia

  6/11/2015

• Provectus Biopharmaceuticals Inc. Retains Allison+Partners As New Media Relations Consultant

  6/2/2015

• Provectus Biopharmaceuticals Inc.’ Abstract On Liver Cancer Accepted For Poster Presentation At 6th Asia-Pacific Primary Liver Cancer Expert Meeting

  5/29/2015

• Provectus Biopharmaceuticals Inc.’s Abstract Accepted For Poster Presentation At 5th European Post-Chicago Melanoma / Skin Cancer Meeting

  5/28/2015